Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 19, 2025 13:00 ET | Source: DelveInsight Business Research LLP

TEPEZZA Market Sales on the Rise Due to the Strong Growth Driven by Demand for Thyroid Eye Disease Treatment | DelveInsight

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- TEPEZZA Market Sales on the Rise Due to the Strong Growth Driven by Demand for Thyroid Eye Disease Treatment | DelveInsight TEPEZZA, as the first...
July 04, 2024 16:00 ET | Source: DelveInsight Business Research LLP

Thyroid Eye Disease Market to Accelerate Substantially by 2034, Assesses DelveInsight | Key Companies Developing Therapies - Viridian Therapeutics, Roche, Immunovant, Amgen, Sling Therapeutics, ACELYRIN, Tourmaline Bio

New York, USA, July 04, 2024 (GLOBE NEWSWIRE) -- Thyroid Eye Disease Market to Accelerate Substantially by 2034, Assesses DelveInsight | Key Companies Developing Therapies - Viridian Therapeutics,...
May 16, 2024 07:00 ET | Source: Tourmaline Bio, Inc.

Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial

Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
March 03, 2021 15:26 ET | Source: The Rosen Law Firm PA

ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – IMVT, HSACU, HSAC, HSACW

NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
October 25, 2017 08:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc Announces First Patient Enrolled in Confirmatory Phase 3 Clinical Trial Evaluating Teprotumumab for the Treatment of Moderate-to-Severe Active Thyroid Eye Disease

DUBLIN, Ireland, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...